Baird analyst Eric Coldwell raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $184 and keeps an Outperform rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $175 from $168 at Barclays
- Quest Diagnostics Reports Strong Growth and Future Confidence
- Morning Movers: UPS and Cigna plunge double digits following Q4 results
- Quest Diagnostics increases quarterly dividend 6.7% to 80c per share
- Quest Diagnostics reports Q4 adjusted EPS $2.23, consensus $2.18